Jiangsu Jibeier Pharmaceutical (688566) Q4 2024 earnings summary

Executive summary

• Achieved total operating revenue of RMB 896.53 million, up 4.14% year-over-year.

• Operating profit reached RMB 254.26 million, a 2.06% increase year-over-year.

• Net profit attributable to shareholders was RMB 218.91 million, down 0.08% year-over-year.

• Total assets at period end were RMB 2.52 billion, up 13.86% from the start of the year.

• Shareholders' equity increased 18.03% to RMB 2.25 billion.

Financial highlights

• Basic EPS was RMB 1.14, a 2.56% decrease year-over-year.

• Net profit excluding non-recurring items was RMB 211.95 million, up 1.35% year-over-year.

• Weighted average ROE was 10.50%, down 1.72 percentage points year-over-year.

• Per-share net assets rose to RMB 11.27, up 11.92% year-over-year.

Outlook and guidance

• Continued focus on team building and market development supported revenue and profit growth.

• Ongoing R&D investment in new drugs, with key projects in advanced clinical trial phases.